## GIANESSI et al U.S. National Phase of PCT/IT03/00007

## **AMENDMENTS TO THE ABSTRACT**

Please insert the Abstract of the Disclosure which is on the attached sheet.

## ABSTRACT OF THE DISCLOSURE

Formula (I) compounds are described: Where the groups are as defined here below, and their use as medinies, particularly as serum glucose and serum lipid lowering agents. Said medicines are useful for the prophylaxis and treatment of diabetes, particularly type 2, and its complications, Syndrome X, the various forms of insulin resistance, and hyperlipidaemias, and present reduced side effects, and, particularly, reduced or no liver toxicity.